SPONSOR

Bristol-Myers Squibb

Total Trials

Recruiting

Phases

Phase 1, Phase 3, Phase 2, Phase 3, Phase 2

Conditions studied: Healthy Volunteers Bipolar-I Disorder With Mania or Mania With Mixed Features Multiple Sclerosis, Relapsing-Remitting Rheumatoid Arthritis Obstructive Hypertrophic Cardiomyopathy (oHCM)Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-small Cell Lung Cancer With MTAP Deletion Hepatic Impairment Carcinoma, Non-Small-Cell Lung Advanced Malignant Tumors

Bristol-Myers Squibb (BMS) is a US biopharmaceutical company with a history spanning over 130 years, today most recognized for its foundational role in developing immune checkpoint inhibitor therapy. BMS scientists were central to discovering the mechanism of CTLA-4 blockade — leading to ipilimumab (Yervoy), the first FDA-approved checkpoint inhibitor in 2011 — and shortly after brought nivolumab (Opdivo), a PD-1 inhibitor, to market. These two agents, used alone and in combination, form the backbone of an immuno-oncology program that spans multiple cancer types and dozens of active Phase 2–3 trials.

Beyond oncology, BMS has significant trial activity in cardiovascular disease (apixaban/Eliquis outcomes studies; investigational fibrin-targeting agents), immunology and fibrosis (iberdomide, mezagitamab for autoimmune diseases), and hematology (including CAR-T therapies through its Celgene acquisition, such as lisocabtagene maraleucel and idecabtagene vicleucel for blood cancers). The Celgene acquisition in 2019 substantially expanded BMS's pipeline, adding multiple myeloma, myelodysplastic syndromes, and lymphoma programs.

BMS conducts clinical research at academic and community sites across more than 50 countries. The company participates in several precision medicine consortia that match patients to trials based on tumor genomic profiling. BMS has also expanded the use of decentralized trial elements — including remote visits, home nursing, and electronic patient-reported outcomes — to reduce the burden of participation for patients with serious illness.

Frequently Asked Questions — Bristol-Myers Squibb

What cancer types does Bristol-Myers Squibb most actively study in clinical trials?

BMS's most active cancer trial areas include melanoma (the original indication for both ipilimumab and nivolumab), non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, colorectal cancer (MSI-H subtype), and multiple myeloma and other hematologic malignancies through its Celgene-derived portfolio. BMS also has substantial early-phase programs in pancreatic cancer, glioblastoma, and triple-negative breast cancer — tumor types with high unmet need and historically poor outcomes.

What is the difference between Opdivo and Yervoy, and are they tested together?

Nivolumab (Opdivo) is a PD-1 checkpoint inhibitor that blocks the PD-1 receptor on T cells, preventing tumor-mediated immune suppression. Ipilimumab (Yervoy) is a CTLA-4 inhibitor that promotes T-cell activation by blocking a different immune checkpoint. The two agents work through complementary pathways, and BMS has demonstrated that combining them (the "Opdivo + Yervoy" regimen) provides durable responses in multiple cancer types — most notably in metastatic melanoma, advanced NSCLC, and pleural mesothelioma. The combination is FDA-approved and also studied extensively in additional indications at varying dose ratios in ongoing trials.

Does BMS offer any patient assistance for clinical trial participation costs?

BMS covers all costs directly related to the investigational treatment itself — including the drug, protocol-required tests, and study visits. Travel assistance, lodging programs, and patient support services vary by trial and site. BMS participates in the Clinical Trial Transportation Program and works with patient advocacy organizations to reduce access barriers. Patients should ask the clinical research coordinator at their enrolling site specifically what financial support is available for their trial, as programs differ between protocols and countries.

Bristol-Myers Squibb

Frequently Asked Questions — Bristol-Myers Squibb

Clinical Trials by Bristol-Myers Squibb

A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis

Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment

A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia

A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)